Laboratorios Farmaceuticos Rovi/€ROVI
1D1W1MYTD1Y5YMAX
Capital at risk
About Laboratorios Farmaceuticos Rovi
Laboratorios Farmaceuticos ROVI SA, ticker ROVI, is a Spain-based pharmaceutical company primarily engaged in developing, manufacturing, and commercializing pharmaceutical products. The company's activities span both domestic and international markets, focusing on a range of medical and drug treatments. Founded in 1946, ROVI continues to expand its reach and influence in the healthcare and pharmaceutical sectors.
- Ticker
- €ROVI
- Sector
- Health
- Primary listing
- BME
- Employees
- 2,470
- Headquarters
- Pozuelo de Alarcón, Spain
- Website
- www.rovi.es
ROVI Metrics
BasicAdvanced
€3B
16.01
€3.62
0.23
€0.78
1.34%
Price and volume
Market cap
€3B
Beta
0.23
52-week high
€86.20
52-week low
€53.00
Average daily volume
95K
Dividend rate
€0.78
Financial strength
Current ratio
2.054
Quick ratio
1.042
Long term debt to equity
0.112
Total debt to equity
0.15
Dividend payout ratio (TTM)
25.83%
Interest coverage (TTM)
37.80%
Profitability
EBITDA (TTM)
175.965
Gross margin (TTM)
64.73%
Net profit margin (TTM)
23.95%
Operating margin (TTM)
19.51%
Effective tax rate (TTM)
21.33%
Revenue per employee (TTM)
€310,000
Management effectiveness
Return on assets (TTM)
9.44%
Return on equity (TTM)
28.65%
Valuation
Price to earnings (TTM)
16.005
Price to revenue (TTM)
3.834
Price to book
4.22
Price to tangible book (TTM)
4.45
Price to free cash flow (TTM)
16.848
Free cash flow yield (TTM)
5.94%
Free cash flow per share (TTM)
3.44
Dividend yield (TTM)
1.34%
Forward dividend yield
1.34%
Growth
Revenue change (TTM)
3.21%
Earnings per share change (TTM)
39.93%
3-year revenue growth (CAGR)
-1.87%
10-year revenue growth (CAGR)
11.79%
3-year earnings per share growth (CAGR)
1.32%
10-year earnings per share growth (CAGR)
22.11%
3-year dividend per share growth (CAGR)
-9.49%
10-year dividend per share growth (CAGR)
21.31%
What the Analysts think about ROVI
Analyst ratings (Buy, Hold, Sell) for Laboratorios Farmaceuticos Rovi stock.
Analyst projections of the future price of Laboratorios Farmaceuticos Rovi stock.
Bulls say / Bears say
ROVI closed the asset purchase agreement with Bristol Myers Squibb to acquire a pharmaceutical manufacturing facility in Phoenix, Arizona, significantly expanding its U.S. CDMO capacity and strategic footprint (Reuters)
ROVI expects its proprietary long-acting injectable Risperidone ISM® (Okedi®) to achieve global sales of €100–200 million in the coming years, diversifying and strengthening its specialty pharma pipeline (Reuters)
The company offers a dividend yield of approximately 1.68%, supported by a consistent 35% payout ratio policy, reflecting solid free cash flow generation (FT.com)
Q1 net profit of €9.4 million in Q1 2026, down 48% year-on-year, highlights significant margin pressure and volatility in ROVI’s earnings (Reuters)
Operating revenue guidance for 2026 was revised down to a low- to mid-single-digit percentage increase versus prior high-single to low-double-digit forecasts, reflecting softer-than-expected pharma demand (Reuters)
Shares trade at €57.25, 33.8% below their 52-week high of €86.55, indicating limited market confidence and upside potential (FT.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
ROVI Financial Performance
Revenues and expenses
ROVI Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ROVI
AllEURGBPUSD
Fund name | Fund size | €ROVI weighting |
|---|---|---|
Xtrackers Spain€XESD | €269M | 0.11% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.07% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.07% |
WisdomTree Global Quality Dividend Growth£GGRG | £1.9B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.